Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...
Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approximately $14 billion. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results